Sorry. Maybe just a question for me on OX40 and the competitive landscape there. I was just considering some recent ...

My name is Julianne, and I will be your conference facilitator today for Amgen's third quarter 2024 financial results ...

STAR-0310 exhibits a long mean half-life of 26 days in cynomolgus monkeys, compared to 10-14 days in a typical non-half-life extended IgG1 antibody, and has comparable potency to rocatinlimab.

Data presentation at a medical congress is anticipated in mid-2025. Rocatinlimab is a first-in-class T-cell rebalancing monoclonal antibody targeting the OX40 receptor. The eight study ROCKET ...

Uplizna and Rocatinlimab are two products garnering attention for their potential in treating generalized myasthenia gravis (gMG) and atopic dermatitis, respectively. Positive data readouts for ...

Data from a Phase 3 study for rocatinlimab is expected this year, while Xaluritamig is a far more speculative opportunity, having not yet progressed into Phase 2 studies. Amgen's CEO, Chairman and ...

In September, we announced positive results from the Phase III Horizon study of rocatinlimab in atopic dermatitis. The study met its co-primary endpoints and all key secondary endpoints.

I was just considering some recent competitive updates like from rocatinlimab, which I think kind of underwhelmed investors. I'm just curious, could you update us or share your thinking on ...

Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts ...